
|Articles|June 13, 2008
Allergan to cash in on eyelash stimulant effect of glaucoma drug
Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement




















